|1.||Scarpa, Maurizio: 3 articles (01/2014 - 09/2013)|
|2.||Tomanin, Rosella: 3 articles (01/2014 - 09/2013)|
|3.||Zanetti, Alessandra: 3 articles (01/2014 - 09/2013)|
|4.||Pardridge, William M: 2 articles (11/2014 - 02/2012)|
|5.||Boado, Ruben J: 2 articles (11/2014 - 02/2012)|
|6.||Gasparotto, Nicoletta: 2 articles (01/2014 - 01/2014)|
|7.||Rampazzo, Angelica: 2 articles (01/2014 - 01/2014)|
|8.||Giugliani, Roberto: 2 articles (09/2013 - 06/2011)|
|9.||Maccarana, Marco: 2 articles (05/2013 - 04/2006)|
|10.||Wood, Tim: 2 articles (01/2013 - 01/2007)|
11/01/2014 - "Mucopolysaccharidosis (MPS) Type II is caused by mutations in the gene encoding the lysosomal enzyme, iduronate 2-sulfatase (IDS). "
09/10/2013 - "Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence."
01/01/2013 - "Mucopolysaccharidosis type II (MPS II) is an inherited X-linked disease associated with a deficiency in the enzyme iduronate 2-sulfatase due to iduronate 2-sulfatase gene (IDS) mutations. "
01/01/2013 - "Mucopolysaccharidosis type II (MPS II) is an X-linked lysosomal storage disorder caused by a deficiency of iduronate 2-sulfatase (IDS). "
08/01/2012 - "A novel iduronate 2-sulfatase mutation in a Chinese family with mucopolysaccharidosis type II."
|2.||Mucopolysaccharidosis II (Hunter Syndrome)
03/01/2007 - "Hunter syndrome (MC KUSIK 309900) or mucopolysacharidosis type II is due to the deficiency of the enzyme iduronate 2 sulfate sulfatase (E.C. "
01/01/2007 - "When the assay was tested on dried blood spots, the iduronate 2-sulfatase activity measured for 13 patients with Hunter syndrome was well below the interval found for 57 randomly chosen newborns. "
01/01/2006 - "Hunter's Syndrome (MPS II) is a class of hereditary disorder characterized by a deficiency of specific enzyme--iduronate sulphatase required to break down mucopolisacharides and occurs in Poland in one of 100-150 thousand male live births. "
04/01/2003 - "Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: identification of 13 novel mutations."
05/01/1999 - "The activity of iduronate sulphatase in the lymphocytes was deficient, which was diagnostic for Hunter syndrome. "
|3.||Deficiency Diseases (Deficiency Disease)
05/01/2013 - "Under pathological conditions such as wound healing, inflammation and cancer, iduronic acid has diverse regulatory functions. "
09/01/2002 - "DS chains of the tumor-associated versican and decorin contained decreased amounts of iduronic acid. "
05/01/2001 - "The amounts of L-iduronic acid-containing disaccharides remained constant, whereas the concentration of D-glucuronic acid-containing disaccharides increased from 2 to 10 times in the tumor, indicating that D-glucuronic acid-containing disaccharides are responsible for the elevation in galactosaminoglycan concentration. "
03/29/1996 - "When completely desulfated and N-resulfated heparin and mouse Engelbreth-Holm-Swarm tumor heparan sulfate were used as acceptors, the purified enzyme transferred sulfate to position 2 of L-iduronic acid residue but did not transfer sulfate to the amino group of glucosamine residue or to position 6 of N-sulfoglucosamine residue. "
04/28/2006 - "The functional relation between dermatan sulfate and cancer is unknown but may involve known iduronic acid-dependent interactions with growth factors, selectins, cytokines, or coagulation inhibitors."
02/01/1995 - "The iduronic acid content of PGIdoA from both types of scar increased in their maturation phase. "
02/01/1995 - "Iduronic acid-rich proteoglycans (PGIdoA) and human post-burn scar maturation: isolation and characterization."
04/30/1996 - "Inseparable iduronic acid-containing proteoglycan PG(IdoA) preparations of human skin and post-burn scar tissues: evidence for elevated levels of PG(IdoA)-I in hypertrophic scar by N-terminal sequencing."
10/25/1990 - "Purification and characterization of iduronic acid-rich and glucuronic acid-rich proteoglycans implicated in human post-burn keloid scar."
03/01/1989 - "Reduction in proteoglycan content, reduced sulfation of keratan sulfate, and accumulation of a high-sulfate, high-iduronic acid dermatan sulfate are previously reported properties of proteoglycan in scar tissue from perforating corneal wounds. "
|5.||Heparitin Sulfate (Heparan Sulfate)
|1.||Hematopoietic Stem Cell Transplantation
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)